This policy governs coverage of pharmacogenetic multi-gene (five or more genes) panel testing for members in the state of Ohio and describes clinical stance, coding references, and applicability to specific tests.
Key ActionWhen requesting authorization for panel-based pharmacogenomic testing, include documentation of how test results will change prescribing for CPIC A/B drug–gene pairs or demonstrate an actionable prescribing decision.
Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.
5+ genesMulti-Gene threshold
Ohio-onlyPolicy scope
D2 (Hayes)PrismRA evidence rating
OR 0.70PREPARE ADR reduction
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
11,060
Real-world cohort
Coverage Criteria and Policy Stance
inv-01: Not medically necessary — Multi-Gene Panels — Covered when ALL of the following are met
Covered when ALL of the following are met
Primary coverage stance: The use of pharmacogenetic multi-gene panels (five or more genes) for the evaluation of drug-metabolizer status is unproven and not medically necessary for any indication due to insufficient evidence of efficacy.
Refer to InterQual CP: Molecular Diagnostics, Pharmacogenomic Testing for Psychotropic Medication Drug Response for medical necessity clinical coverage criteria where applicable.
inv-02: Not medically necessary — PrismRA — 1 top-level node
PrismRA: The PrismRA® molecular signature test is unproven and not medically necessary for evaluating likelihood of inadequate response to anti‑TNF therapies for rheumatoid arthritis due to insufficient evidence of efficacy.
inv-03: Indication-specific evidence summaries — Coverage stance varies by clinical scenario and strength of evidence:
Coverage stance varies by clinical scenario and strength of evidence:
Cardiovascular disease (evidence summary): Evidence is limited; modeling studies suggest multigene PGx at PCI could create genotype‑guided prescribing opportunities (simulations projected 26.5 opportunities per 100 individuals and 39–52% genotype‑guided prescribing at 1–5 years), but high‑quality outcome studies demonstrating improved clinical outcomes are lacking.
Potential coverage only when testing is timed to a specific prescribing decision and when results inform therapy; additional high‑quality studies required.
Anthracycline chemotherapy cardiotoxicity (evidence summary): Multiple systematic reviews and cohort studies identify candidate variants associated with anthracycline‑induced cardiotoxicity and PGx models combining genetic and clinical data show improved predictive AUCs (0.67–0.87), but certainty is very low due to imprecision, inconsistency, publication bias, ethnic homogeneity, and lack of standardized panels; routine PGx panel testing for cardiotoxicity risk is not supported for widespread clinical adoption.
Coverage may be limited to research or specific validated assays; routine panel‑based risk assessment not supported.
Pain management and opioid use (evidence summary): Randomized trials and meta‑analyses report mixed results: some RCTs show reduced opioid use or improved outcomes with genotype‑guided therapy, while others (e.g., small TKA trial) show no difference; overall evidence is limited and heterogeneous.
Coverage may be allowed when PGx testing directly informs an actionable prescribing decision and evidence‑based CPIC guidance exists for the drug/gene pair; otherwise, not routinely covered.
inv-04: Coverage considerations — Summary coverage considerations from available evidence
Summary coverage considerations from available evidence
Multigene PGx general stance: Evidence for broad PGx multigene panel testing to guide individualized therapies (multimorbidity, polypharmacy, cancer toxicity risk, medication response, IBD, and general prescribing) is currently insufficient; clinical efficacy has not been fully substantiated in the literature.
Drawn from statements that evidence is insufficient and clinical efficacy not substantiated.
PrismRA (MSRC) stance: PrismRA (MSRC) has limited, very low‑quality evidence (Hayes D2 rating) with small and heterogeneous studies; additional larger, independent studies are needed and clinical utility is not established for routine coverage.
Multiple cohort studies and a Hayes assessment identified very low quality evidence.
Specific gene testing in oncology: Certain germline variants (e.g., DPYD, NUDT15, TPMT, UGT1A1) are associated with chemotherapy toxicity and may identify patients who could benefit from dose adjustments; randomized evidence (e.g., PREPARE) supports reduction in clinically significant ADRs with panel‑guided prescribing though generalizability is limited.
The policy explicitly states that the use of pharmacogenetic multi-gene panels (five or more genes) for evaluation of drug‑metabolizer status is considered unproven and not medically necessary for any indication due to insufficient evidence of efficacy. The same statement applies to the PrismRA® molecular signature test for predicting inadequate response to anti‑TNF therapies in rheumatoid arthritis. This position is informed by the policy reference to InterQual criteria for molecular diagnostics and the document's unproven/unproven status declarations.
The body of psychiatric evidence is heterogeneous and limited by several consistent methodological concerns: substantial heterogeneity of tests and panels, many trials using proprietary algorithms or differing gene sets, variable study designs and blinding, and a high risk of bias in several analyses. Many primary trials excluded individuals with comorbid psychiatric conditions, reducing generalizability. These limitations undermine broad conclusions about clinical utility for marketed multigene panels without panel‑ and population‑specific validation.
Routine use of multigene PGx panels to assess risk of chemotherapy‑induced cardiotoxicity (e.g., anthracycline cardiotoxicity) or for generalized prediction of cardiotoxicity is not supported by current evidence. Although some candidate variants and predictive models have been reported, certainty is low, panels are not standardized, and additional prospective validation with long‑term follow up is required before routine clinical adoption.
The evidence does not support broad use of multigene PGx panels for indications such as multimorbidity, polypharmacy, general prescribing, cancer treatment toxicity, or routine pain management. While single‑gene testing (for specific drug/gene pairs with established guidance) may be appropriate in selected clinical scenarios, panel‑based testing for wide‑ranging multimorbidity or to predict generalized medication response lacks consistent high‑quality evidence and is therefore not generally supported for routine coverage.
The American Academy of Child and Adolescent Psychiatry (AACAP) recommends that clinicians avoid the use of pharmacogenetic (PGx) testing to select psychotropic medications in children and adolescents, citing limitations in published studies (conflicts of interest, small sample sizes, short follow‑up, and limited applicability when multiple medications are used concurrently). This guidance should inform pediatric ordering and coverage considerations.
Coverage determinations and any exceptions must comply with applicable governing requirements. When applying this policy, reference the relevant federal, state (Ohio Administrative Code), or contractual benefit plan provisions, because those requirements take precedence and may modify coverage or prior authorization expectations.
The policy explicitly describes both pharmacogenetic multi‑gene panels (five or more genes) and the PrismRA® molecular signature test as unproven and not medically necessary. These tests are therefore placed in an unproven/not medically necessary status pending higher‑quality, generalizable evidence of clinical utility.
Recent workgroups and technology assessments (for example, the APA update reviewed by Baum et al.) and independent evaluations (Hayes Molecular Test Assessment of PrismRA) conclude that newly published data do not uniformly support currently marketed multigene panels for routine treatment selection and rate PrismRA evidence as very low quality (Hayes D2). These assessments cite small trials, limited blinding, proprietary algorithms, shifting test versions, and the need for larger, independent validation studies.
Real‑world claims analyses and systematic evaluations have not demonstrated clear outcome improvements with routine PGx panel testing. One large claims‑based cohort found no benefit and higher event rates in tested patients versus controls. Hayes reviews and other assessments similarly found insufficient evidence to support PGx testing for predicting opioid dependence or improving opioid‑related outcomes. These real‑world and review findings contribute to the conclusion that broad routine panel testing has limited demonstrated benefit.
PrismRA (MSRC) and broad pharmacogenetic multigene panels lack sufficient high‑quality evidence of clinical utility to support routine use. Hayes' assessment of PrismRA identified a very low quality evidence base and recommended larger, more rigorous, and independent studies; policy conclusions reflect that these tests remain unproven for routine clinical decision‑making at this time.
Current CPIC guidance supports gene‑level recommendations for specific drug/gene pairs (for example, CYP2C19 and CYP2D6) but does not provide recommendations for the routine use of multigene panels that include five or more genes. CPIC updated SSRI guidance describes where genotypes may be informative, but no CPIC guidance endorses use of broad multigene panels for many indications, underscoring the need for targeted, gene‑specific testing when supported by evidence.
The VA/DOD multidisciplinary work group concluded that evidence was insufficient to recommend either for or against use of PGx testing to guide antidepressant selection in patients with major depressive disorder. That guideline reflects uncertainty in the evidence base and supports cautious interpretation of trial results when forming coverage policy.
The reviewed policy excerpts do not include any additional, explicit standalone statements labeled 'not medically necessary' beyond the primary declarations for multigene panels and PrismRA; however, related not‑covered language and exclusions are described elsewhere in the document and must be interpreted in the context of governing federal/state/contractual requirements.
Indications Where Targeted Testing May Be Considered
inv-53: Refer to InterQual CP: Molecular Diagnostics, Pharmacogenomic Testing for Psychotropic Medication Drug Response for targeted molecular diagnostics.
When medical necessity is established per InterQual CP: Molecular Diagnostics, Pharmacogenomic Testing for Psychotropic Medication Drug Response for targeted molecular diagnostics.
InterQual referral: Medical necessity for targeted molecular diagnostics and pharmacogenomic testing for psychotropic medication drug response will follow the InterQual® CP: Molecular Diagnostics, Pharmacogenomic Testing for Psychotropic Medication Drug Response criteria.
Providers should consult InterQual when seeking medical necessity determinations for targeted psychotropic PGx testing.
inv-54: Major depressive disorder (MDD) — guiding antidepressant selection or switching after inadequate response
Major depressive disorder (MDD) — guiding antidepressant selection or switching after inadequate response
MDD evidence summary: Randomized trials and meta‑analyses report modest early improvements in response or remission with PGx‑guided antidepressant selection (examples: GUIDED, PRIME Care, Oslin et al.); results vary by test, genes included (commonly CYP2C19 and CYP2D6), study design, and population, and not all trials show durable benefits at later timepoints.
Tests and Uses Not Covered
Consistent with the exclusions and not‑medically necessary sections, the policy states that pharmacogenetic multi‑gene panels (five or more genes) and PrismRA are not medically necessary and therefore not covered under the described standard benefit rules. Providers should expect denials or requests for additional justification for these tests unless exceptional governing requirements or contractual terms apply.
Available assessments and recent guideline updates do not universally support currently marketed multigene panels for routine guidance of therapy in major depressive disorder or other psychiatric disorders. Workgroup conclusions cite trial limitations, lack of blinding, proprietary algorithms, and inconsistent primary outcomes; therefore routine coverage of commercially marketed multigene panels for psychiatry is not supported without stronger, test‑specific evidence.
Routine multigene PGx panel testing for prediction of anthracycline‑induced cardiotoxicity and generalized PGx panels for pain management or opioid outcomes is not supported by current evidence. Systematic reviews and cohort studies identify candidate variants and some small trials with mixed results, but overall certainty is low and broader clinical adoption is not justified at this time.
Broad use of pharmacogenetic multigene panels for indications such as multimorbidity, polypharmacy, general prescribing, inflammatory bowel disease, and some cancer contexts is not supported by sufficient evidence. The policy highlights that clinical efficacy has not been conclusively demonstrated across these diverse indications.
No standardization or specific professional guidance exists for panel tests that include five or more genes. The STRIPE Collaborative subcommittee and guideline reviews identified relatively few U.S. clinical practice guidelines addressing broad PGx panels and emphasized variation between organizations; this lack of consensus and standardization supports a non‑coverage stance for unvalidated panels.
Applicable Procedure and Billing Codes
Multi-gene panel minimum gene count
Multi-gene panel minimum gene count>= 5 genes for this policy; CPT 81418 requires >= 6 genes (must include CYP2C19 and CYP2D6 with duplication/deletion analysis).
Documentation Required
Coding and benefit documentation note
Coding and benefit documentation note: The codes listed are for reference only and do not by themselves determine coverage or payment. Providers must obtain prior authorization when required, submit the clinical rationale and required documentation (including genes tested, panel name or laboratory test identifier, clinical indication, prior medication trials when applicable, and timing relative to the clinical decision), and follow centralized test-request workflows when specified by the payer or contractual terms. Failure to supply required documentation, clinical rationale, or to follow prior authorization and centralized evaluation processes may result in denial of benefits. Coverage decisions may change as real-world outcomes and emerging evidence affect clinical utility assessments.
Prior authorization / coding reference: Verify plan-specific PA requirements before ordering.
Prior authorization requirement: Demonstrable impact — orders must include how results will affect current medication selection or management.
Provider Responsibilities, Prior Authorization, and Documentation
Prior Authorization
Follow Ohio policy and payer authorization tools for CPT/PLA-coded PGx tests
This policy applies to Ohio only and references specific CPT/PLA codes (see Applicable Codes). Providers must follow state policy, Ohio Administrative Code requirements, and any payer authorization tools when requesting authorization for pharmacogenomic panel testing.
Follow Ohio Administrative Code 5160-101 for evaluation of unproven services.
Use UnitedHealthcare utilization management tools (InterQual, Medical Policies) when determining prior authorization requirements.
Prior Authorization
Document how results will change prescribing
For panel-based PGx testing requests, include documentation showing how the test result will alter medication selection or dosing (i.e., will change prescribing decisions for medications with CPIC A/B recommendations).
Document the specific medication decision that will be influenced (e.g., CYP2C19 result would change antiplatelet choice after PCI).
Link the reported actionable phenotype to the intended medication change.
Clinical Ordering and Counseling Considerations
Documentation Required
Genetic counseling not mandated here but consider when clinically indicated
The policy does not mandate pre- or post-test genetic counseling in these excerpts, but it highlights the complexity of interpretation and the need for further study; include counseling when local standards or clinical judgment indicate it may aid interpretation.
Consider counseling when test results are complex or when results may alter long-term therapy.
Document counseling provided if performed.
Documentation Required
Document treating clinician and intended medication change for PGx in psychiatry
PGx testing in cited psychiatric trials was ordered by treating clinicians in psychiatric care settings, often to support starting or switching medications; document the treating clinician's role and intended medication change.
Indicate the treating clinician who ordered the test and the medication decision it will inform.
Trials frequently enrolled patients starting or switching antidepressant therapy.
Definitions and Terminology
Multi-Gene Panel — definition and 5+ gene threshold
DefinitionMulti-Gene Panel: Genetic tests that typically use next-generation sequencing to test multiple genes simultaneously; also called multigene test or multiple-gene panel test.
Policy thresholdThis policy addresses Multi-Gene Panel testing that includes five or more genes (>= 5 genes).
Test purposePanels are marketed to proactively evaluate an individual’s possible response to many drugs, in contrast to targeted single-gene tests used for specific medications.
Actionable phenotype (definition)A genotype-predicted metabolic phenotype or variant status that, per guideline (e.g., CPIC) or test algorithm, would prompt a change in medication choice or dosing (examples: CYP2C19 loss-of-function alleles for antiplatelet therapy; CYP2D6/CYP2C19 phenotypes for psychiatric medications).
Background and Evidence Summary
Pharmacogenetics evaluates how genetic variation influences drug response and adverse effects. Single‑gene testing is commonly used when a specific drug/gene interaction has established clinical guidance; multigene panels test multiple genes simultaneously (often via next‑generation sequencing) and are marketed to inform therapy across many drugs. This policy focuses on multigene panels defined as five or more genes and summarizes current evidence across psychiatry, cardiology, oncology, pain management, and rheumatoid arthritis to inform coverage decisions.
Policy Revision History
2026-02-01definition_updateLatest
Updated Definitions section to clarify the meaning of 'Multi - Gene Panel' and archived previous policy version.
2026-02-01supporting_information_refresh
Refreshed Supporting Information sections (Description of Services, Clinical Evidence, FDA, and References) and archived the prior policy version.
Key ActionWhen requesting authorization for panel-based pharmacogenomic testing, include documentation of how test results will change prescribing for CPIC A/B drug–gene pairs or demonstrate an actionable prescribing decision.
Based on large‑scale cancer PGx analyses and PREPARE trial findings.
Randomized evidence for panels: The PREPARE randomized cluster trial of a 12‑gene PGx panel demonstrated a statistically significant reduction in clinically significant ADRs (OR 0.70) in the PGx‑guided arm versus usual care, supporting potential benefit for panel‑based PGx in reducing ADRs; limitations in ancestry diversity and other trial constraints affect generalizability.
RCT supports reduction in ADRs but has limitations.
Coverage may be considered when testing is linked to an imminent prescribing decision and when evidence for the specific panel and algorithm in the treated population is provided.
inv-55: Schizophrenia and bipolar disorder — reducing ADRs and improving outcomes (evidence variable)
Schizophrenia and bipolar disorder — reducing ADRs and improving outcomes (evidence variable)
Schizophrenia/bipolar evidence summary: Some randomized trials and subgroup analyses (e.g., PREPARE psychiatric subgroup; Kang et al. trial in hospitalized Han Chinese men with schizophrenia) suggest potential reductions in adverse drug reactions and improved symptom scores with PGx‑guided care; however, generalizability is limited by ethnicity‑restricted cohorts, small actionable genotype proportions, and trial design limitations.
Coverage may be considered when testing will directly inform an actionable prescribing decision and when test validity in the population is demonstrated.
inv-56: PCI — informing antiplatelet or other cardiology prescribing (e.g., CYP2C19)
PCI — informing antiplatelet or other cardiology prescribing (e.g., CYP2C19)
PCI evidence summary: Cohort analyses and simulation studies indicate that many patients undergoing PCI have actionable genotypes (e.g., CYP2C19) and that panel testing at the time of PCI could create genotype‑guided prescribing opportunities; however, direct high‑quality outcome trials showing improved clinical endpoints are limited.
Testing may be considered when performed at the time of a prescribing decision (e.g., antiplatelet selection) and when linkage to CPIC recommendations is documented.
Periprocedural testing: Modeling and some randomized trials indicate potential prescribing opportunities when PGx testing is performed immediately before a procedure and an imminent medication decision is required (examples include PCI and preoperative pain management for arthroplasty), but evidence is heterogeneous and small trials have mixed results.
Coverage consideration when testing is time‑aligned with an imminent prescribing decision and provides actionable results per CPIC or equivalent guidance.
inv-58: Identification of germline PGx variants to inform chemotherapy dosing (DPYD, NUDT15, TPMT, UGT1A1) and reduce toxicity; panel-guided ADR reduction evidence (PREPARE)
Identification of germline PGx variants to inform chemotherapy dosing (DPYD, NUDT15, TPMT, UGT1A1) and reduce toxicity; panel-guided ADR reduction evidence (PREPARE)
Oncology germline PGx: Studies report clinically relevant germline PGx variants (e.g., DPYD, NUDT15, TPMT, UGT1A1) in a substantial fraction of cancer patients (Leong et al. found 62.7% with variants across four genes) and randomized evidence (PREPARE) demonstrated reduced clinically significant ADRs with panel‑guided therapy (OR 0.70), supporting consideration of PGx testing to inform chemotherapy dosing to reduce toxicity.
Coverage may be considered when testing identifies actionable variants tied to established dosing modifications or alternative therapies.
inv-59: Consider PGx testing before/during pain treatment when toxicity or lack of response concerns exist; CPIC/ISPG support targeted single-gene testing
Consider PGx testing before/during pain treatment when toxicity or lack of response concerns exist; CPIC/ISPG support targeted single-gene testing
Pain management testing guidance: Guidelines and reviews (NCCN, ISPG) support considering PGx testing before or during pain treatment when there are concerns about toxicity or lack of analgesic response; CPIC/ISPG endorse targeted testing for CYP2D6 and CYP2C19 for certain antidepressant and antipsychotic medications and HLA testing prior to carbamazepine/oxcarbazepine, while routine multigene panel testing is not uniformly supported.
Prefer targeted single‑gene testing where CPIC/ISPG guidance exists; consider panels only when individual gene validity and actionable recommendations are established.
inv-60: Various clinical contexts referenced in literature including MDD, schizophrenia, pain, oncology pharmacogenomics, cardiotoxicity risk, and RA therapy response
Various clinical contexts referenced in literature including MDD, schizophrenia, pain, oncology pharmacogenomics, cardiotoxicity risk, and RA therapy response
Contextual evidence summary: A broad body of literature references potential utility of PGx testing across multiple clinical contexts (major depressive disorder, schizophrenia, pain management, oncology pharmacogenomics, cardiotoxicity risk, rheumatoid arthritis treatment response). Evidence strength and applicability vary by indication, test, and population.
Specific coverage determinations should consider indication‑specific evidence, test validity, timing relative to prescribing decisions, and governing contractual/state requirements.
The document excerpts do not list specific individual test exclusions by CPT/PLA code; providers should note that absence of an explicit exclusion in these chunks does not guarantee coverage and that federal, state, or contractual provisions may supersede or modify coverage determinations.
Prior authorization recommended for panel PGx testing: Submit test request with clinical rationale and required panel/gene documentation.
PrismRA prior authorization likely: Proprietary assays often require prior authorization and specific justification.
Centralized evaluation of test requests: Some contracts require approval by a centralized PGx unit or utilization management team; approval is required prior to testing.
Prior authorization: Verify governing requirements — federal, state, and contractual rules may mandate coverage or additional steps.
Denial risk for multi-gene panels: High when clinical utility is not demonstrated for the requested indication or when panel heterogeneity prevents applicability.
Potential denial risk due to insufficient evidence/heterogeneity: Broad panels without patient- or drug-specific justification are more likely to be denied.
Real-world outcomes may affect coverage: Emerging evidence or lack of consistent outcome data can change coverage determinations over time.
Insurance coverage can impede implementation: Lack of coverage or PA can delay or prevent clinically indicated testing.
Approval required by centralized PGx unit (example): Include lab test name, gene list, and intended medication management change when submitting.
State/contractual adherence required: Follow applicable state mandates and member contract terms.
Coding and benefit documentation note: Listed codes are reference-only; inclusion does not guarantee coverage.
Evidence documentation for panel-specific utility: Provide literature or guideline support linking the panel to the clinical scenario when available.
Required test gene/panel documentation: Provide exact panel/gene list, laboratory test identifier (CPT/PLA and lab assay name), specimen type, and analytic methods if requested.
Provider test-order workflow: Confirm PA process, submit required forms, and await centralized approval prior to specimen collection when required.
Submit test request with clinical rationale: Explain current/past medications, response or adverse events, and how results will alter treatment.
Reference governing benefit requirements: Cite member contract, medical policy section, or state law that supports testing or denial.
Prior medication trial documentation: When relevant, document prior medication trials, doses, durations, and failures/intolerances.
Testing timed to clinical decision: Order testing so results will be available to inform imminent medication selection; avoid retrospective or non-actionable timing.
Interaction with step-therapy: PGx testing may interact with step-therapy or other utilization management programs; document how testing affects step-therapy decisions.
Prior Authorization
Prior authorization recommended for multigene PGx panels
Prior authorization is recommended for multigene PGx panel testing because evidence is limited and not uniformly demonstrated to improve outcomes across indications; include clinical rationale tying testing to a specific prescribing decision.
Explain the indication and cite evidence supporting utility for that indication when available.
Tie testing to an imminent prescribing decision when possible.
Prior Authorization
PrismRA testing likely requires prior authorization and extra documentation
PrismRA (MSRC) has very low-quality evidence per Hayes and limited validation; payers may require prior authorization or additional documentation before approving PrismRA testing.
Include any available analytic/clinical validity evidence and rationale for how results will influence b/tsDMARD selection.
Be prepared to provide larger/diverse-study support if available.
Documentation Required
Submit test requests for centralized review when program/provider workflow requires it
Some implementation programs used centralized evaluation of test requests where ordering providers submitted requests to a pharmacogenetic testing unit for triage and approval; consider submitting requests with clinical rationale to a centralized reviewer if applicable.
Example: La Paz Pharmacogenetic Testing Unit reviewed requests and approved 600 of 2,539 consultations after triage.
Provide patient demographics and category of requested marker (A/B/C) as in program workflows.
Verify and follow the applicable federal, state (Ohio Administrative Code), or contractual benefit requirements and UnitedHealthcare utilization management criteria (e.g., InterQual) when determining whether prior authorization is required.
In the event of conflict, federal/state/contractual requirements govern coverage.
Check InterQual CP: Molecular Diagnostics for psychotropic pharmacogenomic medical necessity criteria.
Note
Documentation Required
Document prior inadequate antidepressant trials when relevant
When ordering PGx-guided antidepressant selection after inadequate response, document prior medication trials and failures (e.g., number and duration of antidepressants tried) to justify testing.
Record prior inadequate responses or intolerance to antidepressant therapies and dates of prior trials.
Indicate that many trials enrolled participants with prior inadequate response (average failed medications ~3).
Prior Authorization
Time testing to an imminent prescribing decision
Order testing at a time when results will inform an imminent prescribing decision (e.g., at the time of PCI or preoperative pain management), as some studies and models assume testing performed at those decision points.
State the intended clinical decision point (e.g., antiplatelet selection at PCI).
Timing tied to prescribing increases the likelihood that testing will be considered clinically useful.
Step Therapy
Assess interaction with existing step-therapy requirements
Decision models for PrismRA assumed adherence to test-guided therapy instead of standard stepwise sequencing; verify existing step-therapy requirements and be prepared to justify deviations based on test results.
If test-guided selection would bypass insurer step-therapy, include rationale and evidence supporting that change.
Document that some models assumed full provider adherence to PrismRA recommendations.
Denial Risk
Avoid PGx-based psychotropic selection in children/adolescents per AACAP
AACAP recommends clinicians avoid using PGx testing to select psychotropic medications in children and adolescents; document age-appropriate rationale and consider stepwise clinical approaches before ordering PGx in pediatric patients.
Avoid PGx-directed psychotropic selection in children/adolescents per AACAP guidance.
If ordering, provide justification and evidence for pediatric use and note AACAP recommendations.
Note
Documentation Required
Supply study-specific evidence linking the exact panel to clinical utility
Provide study- or trial-specific evidence demonstrating clinical utility for the exact multigene panel ordered, including the panel's gene list and algorithm, because many RCTs used specific commercial tests with proprietary algorithms and heterogeneous outcomes.
Cite RCTs or meta-analyses that used the same commercial test or demonstrate comparable analytic/clinical validity.
Include the precise genes and any algorithm description used to generate prescribing recommendations.
Documentation Required
Include the specific genes and reported phenotypes on the test report
Document which genes were tested and reported (for example: CYP2C19, CYP2D6, CYP2C9, VKORC1, SLCO1B1) and list actionable variants or phenotype interpretations so results can be mapped to guideline-based prescribing recommendations.
Provide the panel gene list and any deletion/duplication analyses (e.g., CYP2D6 CNV).
Link reported phenotypes to CPIC or other guideline recommendations where applicable.
Documentation Required
Submit orders via centralized test-order workflow where required
Follow provider test-order workflows used in implementation programs where ordering clinicians submitted a recommendation and request to a centralized testing unit for triage and approval.
Be prepared to submit clinical rationale and category of marker (A/B/C) as part of the request.
Centralized programs approved a subset of requests after review (e.g., 600 of 2,539 approved at La Paz).
Documentation Required
Provide clinical rationale with test request
When submitting a test request, include a clear clinical rationale describing the therapeutic question and patient context; in implementation examples this was required for centralized evaluation of appropriateness.
State the therapeutic decision the test will inform and relevant patient history.
Provide demographic details and category of the marker per local triage processes.
Prior Authorization
Reference federal/state/contractual benefit requirements when deciding coverage
When deciding coverage or prior authorization requirements, reference applicable federal, Ohio Administrative Code (OAC), or contractual benefit plan rules because these may override standard policy language.
In event of conflict, federal/state/contractual requirements govern.
Check InterQual for psychotropic pharmacogenomic medical necessity criteria used by UnitedHealthcare.
Denial Risk
High denial risk for multigene PGx panels (5+ genes)
Multigene PGx panels (five or more genes) are considered unproven and not medically necessary for any indication; ordering such panels carries a high risk of coverage denial unless strong, indication- and panel-specific evidence is provided.
Policy states panels of five or more genes are unproven and not medically necessary.
Expect denials for routine multigene panel requests absent robust justification and linkage to a covered indication.
Denial Risk
Denial risk when evidence is insufficient or not generalizable
Trials frequently excluded individuals with comorbid psychiatric conditions and used proprietary algorithms; lack of standardization and high risk of bias may lead to denial if evidence for the specific panel or population is insufficient.
Provide evidence applicable to your patient population; note many trials had restrictive inclusion criteria.
If the test uses a proprietary algorithm, include validation or comparative data.
Denial Risk
Denial risk from unfavorable real-world outcome data
Real-world claims analyses found no improvement in outcomes and in some cases higher event rates among tested patients versus controls; lack of demonstrated real-world benefit can trigger denial or additional review.
Billings et al. found tested patients more likely to experience composite adverse events vs controls.
Be prepared to address real-world outcome data when justifying testing.
Denial Risk
Coverage concerns may prevent use of test results and lead to denial risks
Insurance coverage concerns affected provider uptake of PrismRA results in studies; lack of coverage alignment may impede implementation and lead to denial of testing or downstream therapy changes if payers do not approve test-directed prescribing.
In the PrismRA cohort, deviation from test recommendations was frequently due to insurance coverage concerns.
Document anticipated prescribing actions and coverage pathways to mitigate implementation barriers.
Prior Authorization
Centralized PGx unit approval may be required; many requests are declined
In one centralized program example, a pharmacogenetic testing unit approved only a subset of submitted requests (600 of 2,539), indicating that tests may be denied if not deemed clinically appropriate by a reviewer.
Provide clear clinical justification to improve likelihood of approval.
Be aware that centralized triage programs commonly disapprove a majority of requests.
Denial Risk
Adhere to federal/state/contractual rules to avoid denials
Coverage decisions must adhere to federal, state (OAC), or contractual requirements; failure to follow these governing rules or to document alignment can result in denials.
Federal/state/contractual requirements take precedence over this policy when conflicts exist.
Verify Ohio OAC guidance and contract terms prior to ordering.
Documentation Required
Document pharmacist or treating-physician involvement in ordering/review
Studies describe PGx testing ordered by treating physicians and, in some cases, pharmacist review of results and medication recommendations; include documentation of multidisciplinary review if applicable.
If a pharmacist reviewed PGx results and made recommendations, document that review and any resulting medication changes.
Specify processes used to translate test results into prescribing actions.
Clinical context exampleIn PCI cohorts, genotype results for genes such as CYP2C19 have been used to identify prescribing opportunities for antiplatelet therapy.
Psychiatry examplePsychiatric trials commonly evaluated CYP2D6 and CYP2C19 phenotypes to inform antidepressant selection or dosing after prior inadequate response.
Actionable phenotype/opportunity — genotype result that can change prescribing
Actionable phenotype/opportunity (definition)A genotype or phenotype result that can meaningfully change prescribing (e.g., alter drug choice or dose), as reported when participants had at least one actionable phenotype or projected genotype-guided prescribing opportunities after PCI or in other settings.
Quantitative exampleIn a PCI cohort, 77% had at least one actionable phenotype for five genes and 32% had opportunities for genotype-guided prescribing.
Pain management examplePreoperative PGx evaluation may be reviewed to identify clinically relevant gene–drug interactions and recommend drug- or dose-specific adjustments per CPIC guidance, though trial results are mixed.
Molecular Signature Response Classifier (PrismRA) — key term
PrismRA (MSRC) — key termPrismRA (Molecular Signature Response Classifier) is a Scipher Medicine molecular signature test comprising 19 gene expression features, anti-CCP, and three clinical metrics (sex, BMI, patient disease assessment) intended to predict likelihood of inadequate response to anti‑TNF therapy in RA.
Evidence summaryThe body of evidence supporting PrismRA is limited; Hayes assessment rated the evidence very low (D2) and additional larger, independent studies are needed.
Intended useDesigned to stratify patients before initiating anti‑TNF therapy to guide selection of targeted biologic/DMARD therapy.
Multigene PGx panel — PREPARE study 12-gene example
PREPARE example (12‑gene panel)PREPARE was an open‑label, cluster‑randomized multicenter trial of a 12‑gene PGx panel covering 39 drugs; among participants with actionable results, PGx-guided care reduced clinically significant ADRs (OR 0.70).
Panel scopeThe PREPARE 12‑gene panel was applied across multiple clinical settings and drug classes, demonstrating potential benefit for reducing ADRs but with limitations in diversity and generalizability.
Implication for multigene PGxPREPARE provides randomized evidence supporting potential safety benefits of a multigene PGx panel in a broad population, though further studies are needed for wider adoption.
CPIC — organizationClinical Pharmacogenetics Implementation Consortium (CPIC) is an international organization that produces freely available, peer‑reviewed, evidence‑based, and updatable gene/drug clinical practice guidelines to translate PGx test results into actionable prescribing decisions.
Guideline roleCPIC provides dosing and prescribing guidance for gene–drug pairs (e.g., CYP2D6 and CYP2C19 for antidepressants and tricyclics) based on quality of evidence.
LimitationsCPIC has not issued recommendations for multigene panels that include five or more genes and did not provide recommendations for HTR2A and SLC6A4 due to mixed/insufficient evidence.
Preemptive vs reactive PGx testing categories (A/B/C) — implementation program taxonomy
Categories A/B/C (implementation taxonomy)An implementation program categorized markers as: Category A for preemptive actionable markers (e.g., HLA‑B*57:01), Category B for drugs with well‑defined treatment protocols (e.g., TPMT for thiopurines), and Category C for drugs without well‑defined protocols where utility is assessed case‑by‑case.
Operational exampleLa Paz University Hospital used a centralized Pharmacogenetic Testing Unit to triage requests by category and approved 600 of 2,539 consultation requests; 32% of approved cases had a molecular profile that impacted prescribing.
Testing approach implicationThe taxonomy supports differentiating preemptive screening from indication‑driven testing when evaluating clinical appropriateness of PGx panels.
Multi - Gene Panel — updated definition in Definitions section
Updated definition noteDefinitions section amended to clarify the meaning of 'Multi‑Gene Panel' in the policy (see Policy History/Revision Information dated 02/01/2026).
Existing definition textMulti‑Gene Panel defined as tests that typically use next‑generation sequencing to test multiple genes simultaneously; policy focuses on panels of five or more genes.
Implication for coverageThe amended definition reinforces that the policy applies to multigene panels (>=5 genes) and distinguishes these from single‑gene testing for specific drugs.